The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Central Nervous System Biomarkers-Global Market Insights and Sales Trends 2024
Synopsis
With extensive ongoing development in personalized medicines and the application of biomarkers in diagnosis, the complexity of the central nervous system paves way for the development of biomarkers to enhance early diagnosis of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurological conditions.
The global Central Nervous System Biomarkers market size is expected to reach US$ 5946.9 million by 2029, growing at a CAGR of 5.9% from 2023 to 2029. The market is mainly driven by the significant applications of Central Nervous System Biomarkers in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Central Nervous System Biomarkers market. Safety Biomarker, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Efficacy Biomarker segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Central Nervous System Biomarkers market, driven by demand from China, the second largest economy with some signs of stabilising, the Central Nervous System Biomarkers market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Central Nervous System Biomarkers, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Central Nervous System Biomarkers market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Central Nervous System Biomarkers market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Central Nervous System Biomarkers sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Central Nervous System Biomarkers covered in this report include Merck, Takeda Pharmaceutical, Thermo Fisher Scientific, Avacta Group, Diagenic Asa, Banyan Biomarkers, Eli Lilly, Pfizer and Alseres Pharmaceuticals, etc.
The global Central Nervous System Biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Takeda Pharmaceutical
Thermo Fisher Scientific
Avacta Group
Diagenic Asa
Banyan Biomarkers
Eli Lilly
Pfizer
Alseres Pharmaceuticals
Acumen pharmaceuticals
EKF Diagnostics
Abiant
Myriad RBM
Aposense
Global Central Nervous System Biomarkers market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Central Nervous System Biomarkers market, Segment by Type:
Safety Biomarker
Efficacy Biomarker
Validation Biomarker
Other
Global Central Nervous System Biomarkers market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Central Nervous System Biomarkers companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
With extensive ongoing development in personalized medicines and the application of biomarkers in diagnosis, the complexity of the central nervous system paves way for the development of biomarkers to enhance early diagnosis of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurological conditions.
The global Central Nervous System Biomarkers market size is expected to reach US$ 5946.9 million by 2029, growing at a CAGR of 5.9% from 2023 to 2029. The market is mainly driven by the significant applications of Central Nervous System Biomarkers in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Central Nervous System Biomarkers market. Safety Biomarker, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Efficacy Biomarker segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Central Nervous System Biomarkers market, driven by demand from China, the second largest economy with some signs of stabilising, the Central Nervous System Biomarkers market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Central Nervous System Biomarkers, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Central Nervous System Biomarkers market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Central Nervous System Biomarkers market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Central Nervous System Biomarkers sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Central Nervous System Biomarkers covered in this report include Merck, Takeda Pharmaceutical, Thermo Fisher Scientific, Avacta Group, Diagenic Asa, Banyan Biomarkers, Eli Lilly, Pfizer and Alseres Pharmaceuticals, etc.
The global Central Nervous System Biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Takeda Pharmaceutical
Thermo Fisher Scientific
Avacta Group
Diagenic Asa
Banyan Biomarkers
Eli Lilly
Pfizer
Alseres Pharmaceuticals
Acumen pharmaceuticals
EKF Diagnostics
Abiant
Myriad RBM
Aposense
Global Central Nervous System Biomarkers market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Central Nervous System Biomarkers market, Segment by Type:
Safety Biomarker
Efficacy Biomarker
Validation Biomarker
Other
Global Central Nervous System Biomarkers market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Central Nervous System Biomarkers companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Central Nervous System Biomarkers
1.1 Central Nervous System Biomarkers Market Overview
1.1.1 Central Nervous System Biomarkers Product Scope
1.1.2 Central Nervous System Biomarkers Market Status and Outlook
1.2 Global Central Nervous System Biomarkers Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Central Nervous System Biomarkers Market Size by Region (2018-2029)
1.4 Global Central Nervous System Biomarkers Historic Market Size by Region (2018-2023)
1.5 Global Central Nervous System Biomarkers Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Central Nervous System Biomarkers Market Size (2018-2029)
1.6.1 North America Central Nervous System Biomarkers Market Size (2018-2029)
1.6.2 Europe Central Nervous System Biomarkers Market Size (2018-2029)
1.6.3 Asia-Pacific Central Nervous System Biomarkers Market Size (2018-2029)
1.6.4 Latin America Central Nervous System Biomarkers Market Size (2018-2029)
1.6.5 Middle East & Africa Central Nervous System Biomarkers Market Size (2018-2029)
2 Central Nervous System Biomarkers Market by Type
2.1 Introduction
2.1.1 Safety Biomarker
2.1.2 Efficacy Biomarker
2.1.3 Validation Biomarker
2.1.4 Other
2.2 Global Central Nervous System Biomarkers Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Central Nervous System Biomarkers Historic Market Size by Type (2018-2023)
2.2.2 Global Central Nervous System Biomarkers Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Central Nervous System Biomarkers Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Central Nervous System Biomarkers Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Central Nervous System Biomarkers Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Central Nervous System Biomarkers Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Central Nervous System Biomarkers Revenue Breakdown by Type (2018-2029)
3 Central Nervous System Biomarkers Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Central Nervous System Biomarkers Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Central Nervous System Biomarkers Historic Market Size by Application (2018-2023)
3.2.2 Global Central Nervous System Biomarkers Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Central Nervous System Biomarkers Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Central Nervous System Biomarkers Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Central Nervous System Biomarkers Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Central Nervous System Biomarkers Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Central Nervous System Biomarkers Revenue Breakdown by Application (2018-2029)
4 Central Nervous System Biomarkers Competition Analysis by Players
4.1 Global Central Nervous System Biomarkers Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Central Nervous System Biomarkers as of 2022)
4.3 Date of Key Players Enter into Central Nervous System Biomarkers Market
4.4 Global Top Players Central Nervous System Biomarkers Headquarters and Area Served
4.5 Key Players Central Nervous System Biomarkers Product Solution and Service
4.6 Competitive Status
4.6.1 Central Nervous System Biomarkers Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Merck
5.1.1 Merck Profile
5.1.2 Merck Main Business
5.1.3 Merck Central Nervous System Biomarkers Products, Services and Solutions
5.1.4 Merck Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.1.5 Merck Recent Developments
5.2 Takeda Pharmaceutical
5.2.1 Takeda Pharmaceutical Profile
5.2.2 Takeda Pharmaceutical Main Business
5.2.3 Takeda Pharmaceutical Central Nervous System Biomarkers Products, Services and Solutions
5.2.4 Takeda Pharmaceutical Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.2.5 Takeda Pharmaceutical Recent Developments
5.3 Thermo Fisher Scientific
5.3.1 Thermo Fisher Scientific Profile
5.3.2 Thermo Fisher Scientific Main Business
5.3.3 Thermo Fisher Scientific Central Nervous System Biomarkers Products, Services and Solutions
5.3.4 Thermo Fisher Scientific Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.3.5 Avacta Group Recent Developments
5.4 Avacta Group
5.4.1 Avacta Group Profile
5.4.2 Avacta Group Main Business
5.4.3 Avacta Group Central Nervous System Biomarkers Products, Services and Solutions
5.4.4 Avacta Group Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.4.5 Avacta Group Recent Developments
5.5 Diagenic Asa
5.5.1 Diagenic Asa Profile
5.5.2 Diagenic Asa Main Business
5.5.3 Diagenic Asa Central Nervous System Biomarkers Products, Services and Solutions
5.5.4 Diagenic Asa Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.5.5 Diagenic Asa Recent Developments
5.6 Banyan Biomarkers
5.6.1 Banyan Biomarkers Profile
5.6.2 Banyan Biomarkers Main Business
5.6.3 Banyan Biomarkers Central Nervous System Biomarkers Products, Services and Solutions
5.6.4 Banyan Biomarkers Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.6.5 Banyan Biomarkers Recent Developments
5.7 Eli Lilly
5.7.1 Eli Lilly Profile
5.7.2 Eli Lilly Main Business
5.7.3 Eli Lilly Central Nervous System Biomarkers Products, Services and Solutions
5.7.4 Eli Lilly Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.7.5 Eli Lilly Recent Developments
5.8 Pfizer
5.8.1 Pfizer Profile
5.8.2 Pfizer Main Business
5.8.3 Pfizer Central Nervous System Biomarkers Products, Services and Solutions
5.8.4 Pfizer Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.8.5 Pfizer Recent Developments
5.9 Alseres Pharmaceuticals
5.9.1 Alseres Pharmaceuticals Profile
5.9.2 Alseres Pharmaceuticals Main Business
5.9.3 Alseres Pharmaceuticals Central Nervous System Biomarkers Products, Services and Solutions
5.9.4 Alseres Pharmaceuticals Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.9.5 Alseres Pharmaceuticals Recent Developments
5.10 Acumen pharmaceuticals
5.10.1 Acumen pharmaceuticals Profile
5.10.2 Acumen pharmaceuticals Main Business
5.10.3 Acumen pharmaceuticals Central Nervous System Biomarkers Products, Services and Solutions
5.10.4 Acumen pharmaceuticals Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.10.5 Acumen pharmaceuticals Recent Developments
5.11 EKF Diagnostics
5.11.1 EKF Diagnostics Profile
5.11.2 EKF Diagnostics Main Business
5.11.3 EKF Diagnostics Central Nervous System Biomarkers Products, Services and Solutions
5.11.4 EKF Diagnostics Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.11.5 EKF Diagnostics Recent Developments
5.12 Abiant
5.12.1 Abiant Profile
5.12.2 Abiant Main Business
5.12.3 Abiant Central Nervous System Biomarkers Products, Services and Solutions
5.12.4 Abiant Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.12.5 Abiant Recent Developments
5.13 Myriad RBM
5.13.1 Myriad RBM Profile
5.13.2 Myriad RBM Main Business
5.13.3 Myriad RBM Central Nervous System Biomarkers Products, Services and Solutions
5.13.4 Myriad RBM Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.13.5 Myriad RBM Recent Developments
5.14 Aposense
5.14.1 Aposense Profile
5.14.2 Aposense Main Business
5.14.3 Aposense Central Nervous System Biomarkers Products, Services and Solutions
5.14.4 Aposense Central Nervous System Biomarkers Revenue (US$ Million) & (2018-2023)
5.14.5 Aposense Recent Developments
6 North America
6.1 North America Central Nervous System Biomarkers Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Central Nervous System Biomarkers Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Central Nervous System Biomarkers Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Central Nervous System Biomarkers Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Central Nervous System Biomarkers Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Central Nervous System Biomarkers Market Dynamics
11.1 Central Nervous System Biomarkers Industry Trends
11.2 Central Nervous System Biomarkers Market Drivers
11.3 Central Nervous System Biomarkers Market Challenges
11.4 Central Nervous System Biomarkers Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
